At The Colorado Blood Cancer Institute he developed an investigator initiated a phase 1 protocol for patients with chemotherapy-refractory AML/MDS using GVHD prophylaxis with posttransplant cyclophosphamide followed by PD-1 inhibition with Nivolumab for consolidation. This protocol now offers a potentially curative treatment option for patients that otherwise would not meet criteria to undergo allogenic stem cell transplantation.
Colorado Blood Cancer Institute: 1721 E 19th Ave Ste. 300, Denver, CO 80218, USA
Get the latest thought leadership on Acute Myeloid Leukemia delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Acute Myeloid Leukemia Newsletter" for Acute Myeloid Leukemia news, life
Acute Myeloid Leukemia stories, Acute Myeloid Leukemia clinical trials, Acute Myeloid Leukemia 101 articles and events with Acute Myeloid Leukemia
Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.